{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T18:50:27Z","timestamp":1770576627307,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016802","name":"Natural Science Foundation of Changzhou Municipality","doi-asserted-by":"crossref","award":["CJ20200059"],"award-info":[{"award-number":["CJ20200059"]}],"id":[{"id":"10.13039\/100016802","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Changzhou Third People's Hospital","award":["Key Talents Project"],"award-info":[{"award-number":["Key Talents Project"]}]},{"name":"Changzhou Health Commission","award":["ZD202119"],"award-info":[{"award-number":["ZD202119"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11845-024-03671-z","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T07:10:03Z","timestamp":1711177803000},"page":"1843-1853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association between chitinase-3-like protein 1 and metabolic-associated fatty liver disease in patients with type 2 diabetes mellitus"],"prefix":"10.1007","volume":"193","author":[{"given":"Fan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuowei","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longgen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7650-8842","authenticated-orcid":false,"given":"Wenjian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,23]]},"reference":[{"key":"3671_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7:851\u2013861. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3671_CR2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","volume":"70","author":"F Zhou","year":"2019","unstructured":"Zhou F, Zhou J, Wang W et al (2019) Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatol 70:1119\u20131133. https:\/\/doi.org\/10.1002\/hep.30702","journal-title":"Hepatol"},{"key":"3671_CR3","doi-asserted-by":"publisher","first-page":"e8179","DOI":"10.1097\/MD.0000000000008179","volume":"96","author":"W Dai","year":"2017","unstructured":"Dai W, Ye L, Liu A et al (2017) Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Med (Baltimore) 96:e8179.\u00a0https:\/\/doi.org\/10.1097\/MD.0000000000008179","journal-title":"Med (Baltimore)"},{"key":"3671_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/liv.13994","volume":"39","author":"AE Morrison","year":"2019","unstructured":"Morrison AE, Zaccardi F, Khunti K et al (2019) Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: a meta-analysis with bias analysis. Liver Int 39:557\u2013567. https:\/\/doi.org\/10.1111\/liv.13994","journal-title":"Liver Int"},{"issue":"1999\u20132014","key":"3671_CR5","doi-asserted-by":"publisher","first-page":"<div class=\"Nod","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J et al (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterol 158:1999\u20132014. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312","journal-title":"Gastroenterol"},{"issue":"443\u2013457","key":"3671_CR6","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1053\/j.gastro.2018.04.034","volume":"155","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V et al (2018) Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterol 155:443\u2013457.\u00a0https:\/\/doi.org\/10.1053\/j.gastro.2018.04.034","journal-title":"Gastroenterol"},{"issue":"1611\u20131625","key":"3671_CR7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S et al (2020) Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterol 158:1611\u20131625. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.043","journal-title":"Gastroenterology"},{"key":"3671_CR8","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","volume":"158","author":"TG Cotter","year":"2020","unstructured":"Cotter TG, Rinella M (2020) Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterol 158:1851\u20131864. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.052","journal-title":"Gastroenterol"},{"key":"3671_CR9","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D et al (2022) American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 28:528\u2013562. https:\/\/doi.org\/10.1016\/j.eprac.2022.03.010","journal-title":"Endocr Pract"},{"key":"3671_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/liv.13970","volume":"39","author":"F Procino","year":"2019","unstructured":"Procino F, Misciagna G, Veronese N et al (2019) Reducing NAFLD-screening time: a comparative study of eight diagnostic methods offering an alternative to ultrasound scans. Liver Int 39:187\u2013196. https:\/\/doi.org\/10.1111\/liv.13970","journal-title":"Liver Int"},{"key":"3671_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/hep.27981","volume":"63","author":"EM Koehler","year":"2016","unstructured":"Koehler EM, Plompen EP, Schouten JN et al (2016) Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatol 63:138\u2013147. https:\/\/doi.org\/10.1002\/hep.27981","journal-title":"Hepatol"},{"key":"3671_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110680","volume":"131","author":"S Wang","year":"2020","unstructured":"Wang S, Hu M, Qian Y et al (2020) CHI3L1 in the pathophysiology and diagnosis of liver diseases. Biomed Pharmacother 131:110680. https:\/\/doi.org\/10.1016\/j.biopha.2020.110680","journal-title":"Biomed Pharmacother"},{"key":"3671_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2008.09.016","volume":"50","author":"ML Berres","year":"2009","unstructured":"Berres ML, Papen S, Pauels K et al (2009) A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol 50:370\u2013376. https:\/\/doi.org\/10.1016\/j.jhep.2008.09.016","journal-title":"J Hepatol"},{"key":"3671_CR14","first-page":"172","volume":"53","author":"JS Johansen","year":"2006","unstructured":"Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172\u2013209","journal-title":"Dan Med Bull"},{"key":"3671_CR15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.hbpd.2020.05.009","volume":"19","author":"X Jin","year":"2020","unstructured":"Jin X, Fu B, Wu ZJ et al (2020) Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China. Hepatobiliary Pancreat Dis Int 19:384\u2013389. https:\/\/doi.org\/10.1016\/j.hbpd.2020.05.009","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"3671_CR16","first-page":"337","volume":"26","author":"H Li","year":"2018","unstructured":"Li H, Yan T, Zhu Z et al (2018) Diagnostic value of serum chitinase 3-like protein 1 in chronic liver disease with significant fibrosis and cirrhosis. Chin J Hepatol 26:337\u2013341","journal-title":"Chin J Hepatol"},{"key":"3671_CR17","doi-asserted-by":"publisher","first-page":"35282","DOI":"10.1038\/srep35282","volume":"6","author":"E Kumagai","year":"2016","unstructured":"Kumagai E, Mano Y, Yoshio S et al (2016) Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep 6:35282. https:\/\/doi.org\/10.1038\/srep35282","journal-title":"Sci Rep"},{"issue":"1058\u20131064","key":"3671_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.04.044","volume":"163","author":"CK Lee","year":"2013","unstructured":"Lee CK, Perez-Atayde AR, Mitchell PD et al (2013) Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children\u2019s hospital experience. J Pediatr 163:1058\u20131064. https:\/\/doi.org\/10.1016\/j.jpeds.2013.04.044","journal-title":"J Pediatr"},{"key":"3671_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1089\/omi.2015.0037","volume":"19","author":"H Huang","year":"2015","unstructured":"Huang H, Wu T, Mao J et al (2015) CHI3L1 is a liver-enriched, noninvasive biomarker that can be used to stage and diagnose substantial hepatic fibrosis. OMICS 19:339\u2013345. https:\/\/doi.org\/10.1089\/omi.2015.0037","journal-title":"OMICS"},{"key":"3671_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00109-023-02325-4","volume":"101","author":"AD Kim","year":"2023","unstructured":"Kim AD, Kui L, Kaufmann B et al (2023) Myeloid-specific deletion of chitinase-3-like 1 protein ameliorates murine diet-induced steatohepatitis progression. J Mol Med (Berl) 101:813\u2013828. https:\/\/doi.org\/10.1007\/s00109-023-02325-4","journal-title":"J Mol Med (Berl)"},{"key":"3671_CR21","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1177\/2050640619868352","volume":"7","author":"YJ Zhou","year":"2019","unstructured":"Zhou YJ, Ye FZ, Li YY et al (2019) Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram. United Eur Gastroenterol J 7:1124\u20131134. https:\/\/doi.org\/10.1177\/2050640619868352","journal-title":"United Eur Gastroenterol J"},{"key":"3671_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13098-021-00624-9","volume":"13","author":"W Luo","year":"2021","unstructured":"Luo W, Zhang L, Sheng L et al (2021) Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr 13:6. https:\/\/doi.org\/10.1186\/s13098-021-00624-9","journal-title":"Diabetol Metab Syndr"},{"key":"3671_CR23","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.2337\/db08-0182","volume":"57","author":"AR Nielsen","year":"2008","unstructured":"Nielsen AR, Erikstrup C, Johansen JS et al (2008) Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 57:3078\u20133082. https:\/\/doi.org\/10.2337\/db08-0182","journal-title":"Diabetes"},{"key":"3671_CR24","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatol 65:1557\u20131565. https:\/\/doi.org\/10.1002\/hep.29085","journal-title":"Hepatol"},{"key":"3671_CR25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatol 67:328\u2013357. https:\/\/doi.org\/10.1002\/hep.29367","journal-title":"Hepatol"},{"key":"3671_CR26","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/hep.29302","volume":"66","author":"G Xiao","year":"2017","unstructured":"Xiao G, Zhu S, Xiao X et al (2017) Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatol 66:1486\u20131501. https:\/\/doi.org\/10.1002\/hep.29302","journal-title":"Hepatol"},{"key":"3671_CR27","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","volume":"5","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Ratziu V, Boursier J et al (2020) A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 5:970\u2013985. https:\/\/doi.org\/10.1016\/S2468-1253(20)30252-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3671_CR28","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/hepr.13396","volume":"49","author":"M Higashiyama","year":"2019","unstructured":"Higashiyama M, Tomita K, Sugihara N et al (2019) Chitinase 3-like 1 deficiency ameliorates liver fibrosis by promoting hepatic macrophage apoptosis. Hepatol Res 49:1316\u20131328. https:\/\/doi.org\/10.1111\/hepr.13396","journal-title":"Hepatol Res"},{"key":"3671_CR29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2019633118","author":"N Nishimura","year":"2021","unstructured":"Nishimura N, De Battista D, McGivern DR et al (2021) Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis. Proc Natl Acad Sci USA 118:e2019633118. https:\/\/doi.org\/10.1073\/pnas.2019633118","journal-title":"Proc Natl Acad Sci USA"},{"key":"3671_CR30","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.metabol.2011.09.004","volume":"61","author":"I Kyrgios","year":"2012","unstructured":"Kyrgios I, Galli-Tsinopoulou A, Stylianou C et al (2012) Elevated circulating levels of the serum acute-phase protein YKL-40 (chitinase 3-like protein 1) are a marker of obesity and insulin resistance in prepubertal children. Metab 61:562\u2013568. https:\/\/doi.org\/10.1016\/j.metabol.2011.09.004","journal-title":"Metab"},{"key":"3671_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1210\/jc.2010-0994","volume":"96","author":"V Catalan","year":"2011","unstructured":"Catalan V, Gomez-Ambrosi J, Rodriguez A et al (2011) Increased circulating and visceral adipose tissue expression levels of YKL-40 in obesity-associated type 2 diabetes are related to inflammation: impact of conventional weight loss and gastric bypass. J Clin Endocrinol Metab 96:200\u2013209. https:\/\/doi.org\/10.1210\/jc.2010-0994","journal-title":"J Clin Endocrinol Metab"},{"key":"3671_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020201","author":"S Zhang","year":"2021","unstructured":"Zhang S, Sousa A, Lin M et al (2021) Role of chitinase 3-like 1 protein in the pathogenesis of hepatic insulin resistance in nonalcoholic fatty liver disease. Cells 10:201. https:\/\/doi.org\/10.3390\/cells10020201","journal-title":"Cells"},{"key":"3671_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1440-1746.2009.05806.x","volume":"24","author":"E Hashimoto","year":"2009","unstructured":"Hashimoto E, Farrell GC (2009) Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis? J Gastroenterol Hepatol 24:501\u2013503. https:\/\/doi.org\/10.1111\/j.1440-1746.2009.05806.x","journal-title":"J Gastroenterol Hepatol"},{"key":"3671_CR34","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1136\/gutjnl-2018-317334","volume":"68","author":"VW Wong","year":"2019","unstructured":"Wong VW, Irles M, Wong GL et al (2019) Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut 68:2057\u20132064. https:\/\/doi.org\/10.1136\/gutjnl-2018-317334","journal-title":"Gut"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-024-03671-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-024-03671-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-024-03671-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T10:10:27Z","timestamp":1722507027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-024-03671-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,23]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3671"],"URL":"https:\/\/doi.org\/10.1007\/s11845-024-03671-z","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,23]]},"assertion":[{"value":"29 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Changzhou Third People\u2019s Hospital (decision no. 2020002 of April 23, 2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}